Everwell Health Targets Solubility, Beauty, and Brain Performance

Reporting from SupplySide Connect New Jersey, Everwell Health Chief Science Officer Catherine Kwik-Uribe discussed the company’s latest innovations in ingredient delivery, clinical validation, and functional product development.

A key focus was Everwell’s proprietary Cryopure technology, designed to address one of the biggest formulation challenges in functional beverages: solubility. As ready-to-drink products continue to dominate the market, ensuring active ingredients dissolve effectively while maintaining efficacious dosing is critical. Kwik-Uribe explained that Cryopure enhances the solubility of ingredients like Nitrosigine and nooLVL, enabling formulators to deliver full clinical doses without compromising product quality or consumer experience.

The conversation also explored Lustriva, Everwell’s ingredient targeting hair and skin health. While clinical trials have already demonstrated objective improvements, the company recently conducted an open-label, real-world study to assess consumer perception. Results showed participants reported improvements in hair shine, reduced shedding, and healthier overall appearance, along with smoother and brighter skin. Notably, confidence levels increased significantly, with participants reporting less negative impact of hair concerns on their daily lives after 12 weeks. Kwik-Uribe emphasized that such studies complement traditional clinical data by capturing how consumers actually perceive benefits.

Finally, Kwik-Uribe highlighted Everwell’s targeted ingredients for mood and cognition. EverZen, a botanical derived from corn leaf extract, supports serotonin and melatonin pathways, contributing to improved mood and reduced stress markers like cortisol. Meanwhile, nooLVL enhances nitric oxide production, supporting blood flow, energy perception, and cognitive performance, with clinical data showing benefits in focus, concentration, and working memory.

Together, these innovations reflect a growing emphasis on scientifically validated, consumer-perceptible benefits in functional health products

A transcript of her conversation can be found below.

Nicholas Saraceno: Ladies and gentlemen, reporting live from SupplySide Connect in Secaucus, NJ, I am Nico Saraceno, senior editor for Nutritional Outlook magazine. Today, I’m joined by a very special guest. She is Catherine Kwik-Uribe. She is the chief science officer with Everwell Health. Catherine, thank you so much for joining me today.

Catherine Kwik-Uribe: Thank you for interviewing me today. I'm excited to be here.

Saraceno: Absolutely, and a very busy day here at the show. I was happy to able to get your time for a few minutes amidst the chaos. So let's dive right in with ingredient solubility. Obviously, it's a vital key hurdle when it comes to formulating functional beverages. So how does Everwell Health’s Cryopure technology address these types of challenges, and what kind of effects do you think it'll have on improved solubility when it comes to product performance and consumer experience?

Kwik-Uribe: You can walk on this show floor pretty quickly and see how important functional beverages are. Everyone wants to be able to have a ready-to-drink offering, because people are on the go, and they're not just looking for hydration, they're looking for functional benefits. So last year, at SupplySide Global, we officially launched, and we're happy to showcase here today our Cryopure technology, which is a proprietary technology which allows us to really enhance the solubility of two of our key ingredients, Nitrosigine and nooLVL.

When you think about formulation, you really not only want to make sure that you get the product your ingredient is in, but you get them at the efficacious level. What’s really nice with Cryopure technology is it's allowing us to really allow formulators to get the full effective dose into each serving. It just makes their lives easier, and ultimately allows the consumer to get the real benefit from the product.

Saraceno: That is fantastic. Now let's shift gears to one of your other products, Lustriva. There are recent findings that have come out that highlight improvements in both one, hair appearance, and second, skin appearance, alongside an increase in consumer confidence, which is obviously very important in our industry. How do you view the role of both open-label and real-world studies in complementing your traditional clinical trials when it comes to communicating benefits to brands and consumers? What role do they play in that regard?

Kwik-Uribe: I think you used a great word, it's “complement.” We have clinical evidence that really supports objective measures of improvements in hair and skin, but what we wanted to get out with this study is, are those changes that we objectively measured actually perceived by the consumer? Are they reporting that they notice a difference? That’s how we went into this trial.

We used an open-label design, but we conducted it with a dermatologist. We went through sort of normal channels from a clinical trial perspective, and what we wanted to be able to do was really say with these consumers, how do they report, and do they notice changes in hair and skin? What we found was there was a consistent improvement in how people perceive their hair, so improvements in shine. They saw less shedding, and they felt that their hair was healthier overall.

Then, from a skin perspective, people reported feeling that they perceived that their skin was smoother, brighter, and, once again, overall satisfaction. What's a really exciting takeaway from the study as well is that we also included a validated Quality of Life Survey, which really looks at how people perceive their hair impacting their life.

At the beginning of the study, only about 17% of the people said that there was no effect on their hair impacting their life. By the end of the 12 weeks of the study, that number jumped up to nearly 60%, and people reported feeling more confident. It's really exciting to see this as a complement to the work that we have, which clinically shows objective measures of improvement, now with data that actually consumers are reporting that they actually perceive and feel a difference.

Saraceno: Wow, that's remarkable improvement over that span. You're also showcasing at the show EverZen, which is for mood support. There's nooLVL for cognitive performance. These are positioned around certain physiological outcomes. Can you elaborate on the underlying mechanisms of action for these ingredients, and how does that science translate into measurable benefits for the consumers?

Kwik-Uribe: I'll start with EverZen. So EverZen is a botanical-based ingredient. It's from a corn leaf extract, and it's been specially standardized, with a key bioactive component. Now what's interesting about that bioactive component is it actually seems to work from within the brain and helping to promote the formation of or the synthesis of serotonin and melatonin. Nonetheless, it's not surprising then that when we study the ingredient clinically, that people report improvements in mood and a reduction in stress and feelings of occasional anxiety, and we even saw a reduction in the normal levels of cortisol. You're having these physiological effects as well as with these mood effects. That's pretty exciting.

Then on the other end, we've got another ingredient called nooLVL. And nooLVL is a stabilized form and a bioavailable form of arginine. That's what its key component is. What we know from clinical studies is that key ingredient in nooLVL helps to boost nitric oxide levels within about two hours. We know nitric oxide is really important for helping to support blood flow, which can be really important to how you perceive energy, and can be important for getting blood flow into the brain, which could be important to cognition.

We've actually done some cognitive studies with nooLVL as well, which has shown that it helps to improve short-term focus, concentration, and working memory. We've got these two ingredients, one really helping mood and stress support, and the other one helping to support cognitive abilities.